The manufacturer of a sublingual tablet formulation of buprenorphine plus naloxone this week announced a patient assistance program under which 1,000 patients will receive the opioid dependence medication free of charge.
Under the Orexo US , Inc. program, patients who meet income criteria (household income not over three times the federal poverty level, as well as no insurance coverage that reimburses for the medication) will be able to receive monthly supplies of its ZUBSOLV tablets as prescribed by their doctor. Patients will have to document their eligibility every six months.
The charitable organization NeedyMeds is administering the patient assistance program for ZUBSOLV. The drug manufacturer's president said in an Oct. 7 news release that the company intends to expand the reach of the program as its U.S. business grows.